Alberto Montero, MD

Alberto J. Montero, MD, Department of Hematology and Oncology at Cleveland Clinic, discusses the PERTAIN study in postmenopausal women with hormone receptor-positive, HER2-positive, locally advanced or metastatic breast cancer. The study looks at the impact of adding pertuzumab (Perjeta) to trastuzumab (Herceptin) in aromatase inhibitor (AI) therapy.

Alberto Montero, MD Staff Physician in the Department of Solid Tumor Oncology, Cleveland Clinic, discusses reducing readmission rates for oncology patients.